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Purpose: To investigate the role of MYOC and CYP1B1 in Iranian juvenile open angle glaucoma (JOAG) patients.
Methods: Twenty-three JOAG probands, their available affected and unaffected family members, and 100 ethnically
matched control individuals without history of ocular disease were recruited. Clinical examinations of the probands
included slit lamp biomicroscopy, intraocular pressure (IOP) measurement, gonioscopic evaluation, fundus examination,
and perimetry measurement. Familial cases were classified according to the mode of inheritance. Exons of MYOC and
CYP1B1 were sequenced, and novel variations assessed in the control individuals. Potential disease-associated variations
were tested for segregation with disease status in available family members.
Results: The mode of inheritance of the disease in the families of four probands (17.4%) appeared to be autosomal
dominant and in at least eight (34.8%) to be autosomal recessive. Four patients carried MYOC mutations, and an equal
number carried CYP1B1 mutations. The MYOC mutations were heterozygous; two of them (p.C8X and p.L334P) are
novel, and one codes for the shortest truncated protein so far reported. Autosomal recessive inheritance was consistent
with inheritance observed in families of patients carrying CYP1B1 mutations. All these patients carried homozygous
mutations.
Conclusions: MYOC and CYP1B1 contributed equally to the disease status of the Iranian JOAG patients studied. The
contribution of the two genes appeared to be independent in that no patient carried mutations in both genes. The fraction
of Iranian patients carrying MYOC mutations was comparable to previously reported populations.
Glaucoma  is  a  heterogeneous  group  of  optic
neuropathies, which manifest by optic nerve head cupping or
degeneration of the optic nerve, resulting in a specific pattern
of visual field loss [1-3]. Increased intraocular pressure (IOP)
is often associated with the condition. If not treated by medical
or surgical therapy in time, glaucoma leads to irreversible
visual  field  loss  and,  ultimately,  blindness.  Therefore,
diagnosis at an early stage of the disease is very important.
The  disease  affects  approximately  65  million  people
worldwide and is considered the second leading cause of
blindness  [4].  Glaucoma  in  some  families  demonstrates
Mendelian  inheritance.  It  is  sub-grouped  into  three  major
classes  on  the  basis  of  etiology,  anatomy  of  the  anterior
chamber, and age of onset [1]. Primary open-angle glaucoma
(POAG; OMIM 137760) accounts for 70% of glaucoma cases
in Caucasian populations and usually affects individuals past
the age of 40 [5]. In this form of glaucoma, the anterior
chamber angle and the trabecular meshwork appear normal.
It  is  associated  with  variable  severity  and  phenotypic
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expressivity [6,7]. POAG is sometimes divided into the two
sub-classes  of  adult-onset  and  juvenile-onset,  the  latter
appearing between early childhood and the age of 40 [7]. The
more rare juvenile form (JOAG) has been reported to usually
exhibit autosomal dominant inheritance. Clinical features of
the juvenile form are generally more severe [6].
Although  many  loci  have  been  reported  for  POAG,
(GLC1A to GLC1N; Human Gene Nomenclature), genes for
only three have been identified [2]. The three genes code for
myocilin  (MYOC;  GLC1A;  OMIM  601652),  optineurin
(OPTN; GLC1E; OMIM 602432), and WD repeat containing
protein  36  (WDR36;  GLC1G;  OMIM  609669)  [7-9].  The
functions of these genes in the eye are not known. Myocilin
is a bipartite protein, containing a myosin-like NH2-terminal
domain  and  an  olfactomedin  homology  COOH-terminal
domain  [10].  Most  of  disease-associated  mutations  in
MYOC  affect  the  olfactomedin-like  domain.
Haploinsufficiency does not appear to be the primary disease
mechanism of MYOC mutations [11]. Several studies have
indicated that mutant forms are associated with a gain of
function or negative dominant effect [10,12-15]. Mutations in
MYOC have been found in sporadic cases and in patients
inheriting the disease in an autosomal dominant fashion, most
often  in  those  with  juvenile  onset  [6,7,16,17].  There  is
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508evidence that interactions between different genes may cause
glaucoma in some individuals [18-22].
CYP1B1  (OMIM  601771),  encoding  cytochrome
P4501B1,  is  a  gene  commonly  associated  with  primary
congenital  glaucoma  (PCG;  OMIM  231300);  however,
mutations in CYP1B1 have been reported in JOAG patients
[23-27].  Some  patients  carrying  CYP1B1  mutations  also
carried MYOC mutations and the etiology of disease in these
was  considered  digenic.  The  pathway  by  which  CYP1B1
causes  glaucoma  is  not  understood  [26,27].  PCG  is
characterized  by  an  anatomic  defect  of  the  trabecular
meshwork (trabeculodysgenesis) and an age of onset in the
neonatal or infantile period.
The genetic basis of PCG among Iranian patients has
recently been studied, and it was found that nearly 70% of
Iranian PCG patients carry disease-associated mutations in
CYP1B1 [28]. In other populations, mutations in CYP1B1
account for the disease status of 20%–100% of PCG patients
[29]. A heterogeneous range of mutations were identified
among the Iranian patients, many of which were novel. Here,
we assess the association of MYOC and CYP1B1 in a cohort
of 23 Iranians affected with JOAG. Phenotypic features of
patients carrying mutations in these genes are presented.
METHODS
This  research  was  performed  in  accordance  with  the
Declaration of Helsinki and with the approval of the Ethics
Board of the International Institute of Genetic Engineering
and Biotechnology in Iran. The participants or authorized
family  members  all  consented  to  participate  after  being
informed of the nature of the research. Twenty-three unrelated
JOAG patients were recruited from the ophthalmic division
of  the  Labafi-Nejhad  Hospital  (associated  with  Shahid
Beheshti University of Medical Sciences and Health Services)
in Tehran. The hospital is a national reference center and
patients from throughout Iran are referred to it. All patients
were diagnosed by one of the authors (S.Y.) who is a glaucoma
specialist.  Slit  lamp  biomicroscopy,  IOP  measurement,
gonioscopic evaluation of the angle, fundus examination, and
measurement  of  perimetry  were  performed  whenever
possible. IOP measurements were obtained using Goldmann
tonometry. Criteria for diagnosis were the presence of at least
two of these criteria: an IOP greater than 21 mmHg in at least
one  eye  or  intereye  IOP  asymmetry  exceeding  8  mmHg;
characteristic glaucomatous optic nerve head or retinal nerve
fiber layer (RNFL) changes (e.g., vertical cupping, neural rim
thinning or loss, RNFL dropout); and visual field defects not
attributable to other causes. All patients presented with an
open anterior chamber angle in the affected eyes. Patients with
other  ocular  or  systemic  anomalies  were  excluded.
Classification of juvenile onset POAG was based on the age
of diagnosis, ranging between the age of 10 and 40 years. One-
hundred  ethnically  matched,  unrelated  control  individuals
were also recruited from those older than 60 years of age and
without self-reported familial history of ocular diseases.
The three exons of MYOC were amplified by polymerase
chain  reaction  (PCR;  primer  sequences  available  upon
request). All PCR products were sequenced in both forward
and reverse directions with the same primers used in the PCRs,
using the ABI big dye chemistry and an ABI Prism 3700
instrument (Applied Biosystems, Foster City, CA). Sequences
were  analyzed  by  comparing  them  to  MYOC  reference
Figure 1. Iranian JOAG pedigrees. (A)
JG 102: Inheritance in this pedigree does
not appear to be conclusively autosomal
dominant  because  individuals  of
generation I are unaffected. Autosomal
recessive  inheritance  seemed  possible
because of consanguinity and extensive
inbreeding in village of residence. (B)
JG  103  and  (C)  JG  111:  Autosomal
recessive  inheritance  is  suggested  in
these two pedigrees because of multiple
affected  siblings  born  to  unaffected
parents who are first cousins. (D) JG
118: Autosomal dominant inheritance is
suggested  in  this  pedigree  because
affected  individuals  are  observed  in
three  consecutive  generations.  The
affected  individuals  of  the  last  two
generations each had only one affected
parent.
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509sequences  (NT_004487,  NM_000261,  and  NP_000252)
using  the  Sequencher  software  (Gene  Codes  Corp.,  Ann
Arbor, MI). To determine segregation of found variations with
disease  status  in  families,  appropriate  restriction  enzyme
digestion reactions were set up and restriction fragment length
polymorphism  (RFLP)  was  performed.  Similarly,  the
presence  of  novel  variations  in  control  individuals  was
assessed by RFLP. Predicted effects of variant sequences on
splicing  were  determined  by  comparison  with  known
canonical splice site motifs at the splice site prediction by
neural network site. To assess the extent of conservation of a
novel  variation  in  MYOC  thought  to  be  associated  with
disease, the amino acid sequences of 12 myocilin proteins
from  as  many  species  were  obtained  from  SwissProt  and
aligned  using  the  ClustalW  software  (European
Bioinformatics  Institute,  Hinxton,  UK).  Core  haplotypes
defined by three common MYOC intragenic polymorphisms
were assessed in the probands using PLINK.
For mutation analysis of CYP1B1, coding exons 2 and 3
of CYP1B1 were sequenced and the sequences were analyzed
as already reported [28]. Exon 1 of CYP1B1 was not analyzed
because  no  disease-associated  variations  have  been  found
among  the  many  PCG  patients  screened  from  various
populations [28,29].
RESULTS
The clinical features of the sporadic JOAG patients and the
probands  of  the  familial  cases  are  presented  in  Table  2.
Average age of onset of the patients was 21.3 years old.
The patients were recruited consecutively without regard
to familial status of disease. Patients were designated sporadic
if they reported no consanguinity between parents and no
other incidence of disease among relatives. If the previous
criteria did not apply, they were designated familial. The mode
of inheritance before mutation analysis in some familial cases
was not straightforward and these were indicated as unknown.
Parent to child inheritance was not necessarily an indication
of  autosomal  dominant  inheritance  because  of  extensive
inbreeding  in  some  pedigrees,  and  reported  non-
consanguinity may have been misleading as all individuals
within  a  pedigree  sometimes  belonged  to  small  isolated
villages  where  consanguineous  marriages  were  common.
Classification  was  further  hampered  because  of  possible
incomplete penetrance of both CYP1B1 and MYOC mutations
[24,30-32]. An example of a pedigree (JG 102) in which the
mode  of  inheritance  was  initially  difficult  to  establish  is
presented in Figure 1A. For families where the mode of JOAG
inheritance  was  clear,  it  was  designated  as  autosomal
recessive  or  autosomal  dominant.  The  designations  are
presented in Table 1, and some pedigrees are shown in Figure
1.
Seven sequence variations were identified in the MYOC
gene of the Iranian JOAG patients (Table 3). Four of the
variations,  c.-83G>A,  c.227G>A,  IVS2+35G>A,  and  c.
975G>A  are  single  nucleotide  polymorphisms  (SNPs)
previously reported not to be associated with disease [11,16,
33,34]. The first three SNPs were common among our cohort
of  patients  and  were  found  in both  the  heterozygous  and
homozygous states. C.975G>A was observed in only one
patient  in  the  heterozygous  state.  Core  intragenic  SNP
haplotypes  defined  by  the  three  common  variants  were
assessed for the two MYOC alleles of all the patients (Table
2). Seventeen of the probands were homozygous at all or
heterozygous at most at one of these variant positions, and
their haplotypes could therefore be defined unambiguously
Four haplotypes, –GGG- (H1), -GGA- (H2),–AAA- (H3), and
–AAG- (H4), that are defined by nucleotides at positions
c.-83, c.227, and IVS2+35 were observed. H1 (47.7%) and H2
(36.4%) were by far the most common haplotypes in our
cohort of patients.
C.24C>A and c.1001T>C are novel sequence variations
in MYOC (Figure 2). C.24C>A, observed in the heterozygous
state in two patients (JG 123 and JG 130), creates a stop codon
early in the coding sequence after the seventh amino acid
residue  (C8X).  It  is  thought  to  be  associated  with  JOAG
because it was found in two unrelated sporadic JOAG patients,
TABLE 1. MODE OF JOAG INHERITANCE IN FAMILIES OF PATIENTS.
Sporadic cases Familal cases Mode of Inheritance of familial cases
Consanguious parents >1 Affected
individual
Consanguious parents &
>1 affected individual
Autosomal
dominant
Autosomal recessive Unknown
JG104 JG107 JG102 JG100 JG113 JG101 JG100
JG120 JG113 JG101 JG117 JG103 JG102
JG123 JG114 JG103 JG118 JG105 JG110
JG127 JG117 JG105 JG121 JG107 JG112
JG130 JG121 JG110 JG111 JG122
JG122 JG111 JG114 JG134
JG129 JG112 JG129
JG134 JG118 JG131
JG131
Sporadic cases are indicated in the left-most column. The next three columns separate the familial cases according to criteria
by which they were classified as familial. The three right-most columns indicate mode of inheritance in each of the familial
cases.
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510shown to be absent by RFLP in the DNA of three available
unaffected family members, and shown to be absent by RFLP
in 100 control individuals (not shown). Identity by descent of
the C8X mutation in the two patients could not be established
as it was associated on haplotype H1 in one (JG 123) and on
haplotype H1 or H2 in the other (JG 130). C.1001T>C, which
results in L334P in the olfactomedin domain, is also thought
to be associated with disease status. It results in an amino acid
alteration at a position completely conserved in the myocilin
protein of 12 species, including species as distally related as
human and zebrafish (Table 4; bold, underlined amino acid).
The  variation  was  found  in  one  patient  (JG  102)  in  the
heterozygous state on haplotype background H2. It was shown
by RFLP to segregate with disease status among available
members of this family (Figure 1A). Additionally, it was not
observed by RFLP in the DNA of 100 ethnically matched
control individuals (not shown). Age of diagnosis of the four
affected family members was between 7 and 20 years old. The
variation c.1109C>T resulting in P370L in the olfactomedin
domain,  was  found  in  one  sporadic  case  (JG  104)  in  the
heterozygous  state  on  haplotype  H2.  This  variation  has
previously been reported as a disease-associated variation in
several populations [34-36]. It is likely to be the cause of
JOAG  in  patient  JG  104.  Unfortunately,  other  family
members were not available for genetic analysis.
Four  of  the  Iranian  JOAG  patients  carried  disease-
associated mutations in the CYP1B1 gene. All four carried the
mutations in the homozygous state. C.182G>A (g. 3987G>A),
causing G61E, was observed in three of the JOAG patients
(JG 100, JG 103, and JG 114), and c. 1103G>A (g. 7940G>A),
causing R368H, was observed in one patient (JG 129). The
patient carrying R368H was affected with PCG in one eye
(onset at birth) and with JOAG in the other. G61E and R368H
have previously been reported to cause PCG in patients of
various ethnicities, and they are common mutations among
Iranian PCG patients [28]. The mode of inheritance in the
pedigrees of three of the JOAG patients (JG 103, JG 129, and
JG 114) was clearly autosomal recessive (Table 1). Affected
TABLE 2. PHENOTYPIC FEATURES OF IRANIAN JOAG PATIENTS.
Pedigree F/S Inheritance Age at diagnosis C/D ratio R/L IOP max (mmHg)
R/L
Trabeculotomy Age of onset
range
MYOC Haplotype
JG104# S 14 years 0.3/0.6 30/34 1x H1, H2*
JG120 S 40 years 0.6/0.6 40/40 1x H1, H1*
JG123# S 17 years 0.3/0.4 22/29 1x H1, H1*
JG127 S 32 years 0.3/0.3 30/30 1x H1, H1*
JG130# S 14 years 0.3/0.5 20/30 1x H1, H2*
JG113 F AD 40 years 0.5/0.9 multiple 5–40 years H2, H3
JG117 F AD 17 years 0.9/0.4 34/34 1x 17–22 years H2, H3
JG118 F AD 17 years 33/33 2x Birth-60
years
H1, H1*
JG121 F AD 27 years 0.3/0.4 33/34 1x 27–58 years H1, H2*
JG101 F AR 16 years 0.6/0.3 33/34 2x Birth-22
years
H1, H2*
JG103## F AR 19 years 0.5/0.5 /33 1x 19–20 years H1, H3 or
H2, H4
JG105 F AR 24 years normal/33 1x 24–29 years H2, H2*
JG107 F AR 10 years 0.3/0.3 1x H2, H2*
JG111 F AR 32 years high/high 2x 32–36 years H1, H2*
JG114## F AR 18 years 0.3/0.3 1x 5–30 years H3, H3*
JG129## F AR L: birth
R: 12 years
0.6/0.3 30/ Birth-12
years
H1, H1*
JG131 F AR L: 12 years
R: birth
0.5/0.3 28/24 1x Birth-45
years
H1, H4
JG100## F ? 10 years 0.5/0.6 35/35 3x Birth-12
years
H1, H2*
JG102# F ? 19 years 0.5/0.3 33/34 1x 7–20 years H2, H2*
JG110 F ? 14 years 0.5/0.3 2x 14–35 years H2, H2*
JG112 F ? 30 years 0.5/0.5 1x 5–60 years H1, H1*
JG122 F ? 25 years 0.3/0.3 1x H1, H4
JG134 F ? 30 years 0.4/0.9 34/34 H1, H4
Unknown clinical features are left blank. For familial cases, features of the proband of the families are presented. The meaning
of each symbol and abbreviation is given in the following: F/S indicated the familial/sporadic status of patients: F, familial; S,
sporadic; AD: autosomal dominant; AR: autosoamal recessive; ?: unknown mode of inheritance; R: right eye; L: left eye; Age
of onset range is the range of age of onset in other affected family members; MYOC haplotypes are defined by SNPs at positions
c.-83, c.227, and IVS2+35 in the same order. H1: -GGG-, H2: -GGA-, H3: -AAA-, H4: -AAG-; The sharp (hash mark) indicates
patients in whom MYOC disease-associated variations were found; the double sharp indicates patients in whom CYP1B1 disease-
associated variations were found; the asterisk indicates that the haplotypes of these patients were unambiguous. Those of the
remaining patients were predicted.
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512siblings  from  only  one  of  the  pedigrees  (JG  103)  were
available for genetic analysis, and it was shown by RFLP that
they all carried homozygous CYP1B1 mutations (Figure 1B).
Unfortunately, unaffected siblings in the four pedigrees with
CYP1B1 mutations were not available for genetic analysis.
However, some of the 14 unaffected siblings are expected to
be heterozygous on a statistical basis. Similarly, the parents
of three of the probands, all of whom are expected to harbor
at least one mutated CYP1B1 allele, were self-reported not to
be affected with an ocular disorder. It has been reported that
parents of PCG patients, many of whom carried the same
G61E  mutation  found  in  three  of  our  patients,  are  not  at
increased risk of developing glaucoma [30]. The father in the
fourth pedigree (JG 100) was affected, but he was an offspring
of a consanguineous marriage in a highly inbred pedigree,
making  it  possible  that  he  too  was  homozygous  for  the
CYP1B1 mutation. There was no obvious difference between
age  at  diagnosis  and  phenotypic  features  of  patients  with
MYOC and CYP1B1 mutations.
DISCUSSION
Our cohort of JOAG patients had two notable features. One is
that of the patients whose disease was classified as familial,
four belonged to pedigrees in which the mode of inheritance
of disease was autosomal dominant while eight belonged to
pedigrees with an autosomal recessive mode of inheritance
(Table 1). Although autosomal recessive inheritance of JOAG
has been reported, the inheritance of the disease for familial
cases is generally considered to be autosomal dominant [1,6,
36,37]. JOAG is caused by more than one gene, and some of
the genes may exert their effect in a recessive fashion. The
role of these genes is less likely to be discerned in genetic
studies on populations where consanguineous marriages are
infrequent, and most of the studies on JOAG have been done
on  such  populations  [35].  The  relatively  high  rate  of
inbreeding within the Iranian population is expected to allow
mutations in these putative genes to show their phenotypic
effects. It would be of interest to establish whether autosomal
recessive  inheritance  of  JOAG  is  common  in  other
populations where consanguineous marriages are common
such as the population of Saudi Arabia.
Another interesting feature of our cohort is that among
the  17  families  in  which  more  than  one  individual  was
affected, one member in five of the families (29.4%) was
affected from the time of birth and could be classified as a case
of primary congenital glaucoma (Table 2). The preponderance
of this situation in multi-case families supports the proposal
made by other investigators that the disturbance of common
biochemical pathways may be involved in the etiology of PCG
and JOAG [20,24,38]. The observations of PCG (onset at
birth) in one eye and JOAG (onset at age of 12) in the other
eye of two probands (JG 129 and JG 131) further support this
conjecture.
A mutation in MYOC was assessed to be the cause of
JOAG in 4 of the 23 probands (17.4%) screened. This figure
falls within the range reported for other populations [6,16,
17]. C.24C>A that causes C8X was a novel disease-associated
variation observed in two unrelated patients. The phenotypic
features of the two patients, including age at diagnosis, cup to
disc ratio, and IOP, were quite similar (Table 2). The protein
product of the mutated allele is expected to be the shortest
truncated MYOC reported to date. In addition to causing early
protein truncation during protein synthesis, the early nonsense
codon  may  also  result  in  reduced  levels  of  mRNA  [39].
Previously, mutation Arg46X was reported in patients from
Korea, Japan, and China [17,33,36], all countries in the Far
East. After initial association of Arg46X and several other
variations in MYOC with glaucoma, the causative nucleotide
changes  were  also  identified  in  control  individuals  [33,
40-42].  The  absence  of  a  tight  association  between  the
variations  and  disease  phenotype  is  a  reflection  of  the
complexity of the etiology of glaucoma [35]. With regards to
C8X, the causative mutation was absent in the DNA of three
Figure 2. Novel mutations in MYOC. A: At the top, the sequence
chromatogram  is  showing  the  heterozygous  mutation,  c.24C>A,
which causes the codon change UGC to UGA, resulting in C8X; at
the bottom, the chromatograph shows the wild type sequence. B: The
top sequence chromatogram shows the heterozygous mutation, c.
1001T>C, which is causing codon change CUU to CCU, resulting in
L334P; the bottom chromatograph illustrates the wild type sequence.
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513unaffected siblings (age 25–28 years old) and 100 control
individuals. On the other hand, at least one parent of each of
the probands is expected to have harbored the variation. Both
parents of both probands were reported by the probands not
to have any form of ocular disorder, suggesting incomplete
penetrance. Unfortunately, the parents were not available for
genetic analysis. C8X may accompany a normal phenotype
within specific genetic and/or environmental backgrounds,
and an assessment of its penetrance must await studies in
larger cohorts of affected and normal controls. If indeed C8X
can cause JOAG as it appears to do in the probands of JG 123
and JG 130, this raises questions with regards to a gain of
function  or  negative  dominant  effect  model  of  disease
causation by MYOC mutations [10,12,13]. Either the mRNA
or the very short truncated protein product of the mutated
allele can exert the same effect, or other models such as
haploinsufficiency must be considered for at least some of the
variations [12,13,43].
In addition to C8X, L334P was a novel disease-associated
variation  found  among  the  Iranian  pedigrees.  Given  that
approximately 70 glaucoma-associated variations have been
identified in MYOC among the many patients screened in the
10 years since the discovery of the gene, finding two novel
mutations among only 23 probands is notable. This finding
testifies to the high heterogeneity of the Iranian population
and the potential value of this population for genetic studies
[28,43,44]. With respect to MYOC, no single mutation has yet
been observed in Caucasian, African, and Asian populations,
and many mutations have been found in only specific regions
[35,45-47].  As  C8X  was  found  in  two  unrelated  Iranian
patients  and  not  found  in  other  countries,  it  may  have
originated in Iran and so far have spread only to individuals
within this region. MYOC mutations are generally considered
relatively recent in human history [35]. C8X occurred on
intragenic haplotype H1 and possibly H2, and L334P occurred
on  intragenic  haplotype  H2  (see  Table  2).  In  case  these
variations  are  found  in  the  future  in  other  populations  in
association with different haplotypes, the observation will be
an indication of a recurrence of mutation.
P370L is one of the few MYOC mutations likely to have
occurred more than once in human history [48]. The mutation
in the Iranian proband is associated with haplotype H2, but
available information does not allow us to ascertain whether
it shares ancestry with previously reported P370L alleles or
represents an independent mutation event.
Homozygous mutations in CYP1B1 were assessed to be
the cause of JOAG in 4 of the 23 probands (17.4%) screened,
the  same  number  as  those  whose  disease  was  caused  by
MYOC. Mutations in MYOC were not observed in any of these
four patients, and none of the individuals in our cohort were
observed  to  carry  only  a  single  mutated  CYP1B1  allele.
Patients  affected  with  primary  congenital  or  open  angle
glaucoma carrying double heterozygous mutations, one in
CYP1B1  and  the  other  in  MYOC,  have  previously  been
reported in three studies [20,24,49]. The authors suggested
that  CYP1B1  may  act  as  a  modifier  locus  for  MYOC  in
promoting open angle glaucoma. In another study, among a
large cohort of 236 French Caucasian POAG patients (with
the median age of 48 years at diagnosis), 12 individuals (5.1%)
carrying CYP1B1 mutations were identified [21]. Only one
CYP1B1  mutated  allele  was  found  in  10  of  them,  and  a
MYOC mutation was not found in any of the 12 patients. It
was suggested that a modifying locus other than MYOC or
environmental factors may be involved in the disease status
of  the  patients  carrying  heterozygous  CYP1B1  mutations.
Similarly, in a recent study on 200 POAG patients from India,
CYP1B1 mutations were identified in nine patients (4.5%) and
only one of these nine patients carried two mutated alleles
[23]. This JOAG patient was reported not to harbor mutations
in MYOC and OPTN, and it was suggested that CYP1B1 was
the primary cause of his disease status. Finally, in a study on
82  Spanish  POAG  patients,  nine  persons  (10.9%)  were
reported to carry one putative disease-causing CYP1B1 allele;
none  carried  two  mutated  alleles  [25].  Both  CYP1B1
TABLE 4. ALIGNMENT OF L334P IN MYOCILIN PROTEINS.
Gene L334P Seq ID
MYOC_Homo sapiens GAVVYSGS L YFQGAES NP_000252.1
MYOC_Canis lupus familiaris GAVVYRGS L YFQGAGS NP_001041495
MYOC_Canis familiaris GAVVYRGS L YFQGAGS Q2PT31
MYOC_Felis catus GAVVYWGS L YFQGAES AAS68633.1
MYOC_Pan troglodytes GAVVYSGS L YFQGAES XP_513995.2
MYOC_Macaca fascicularis GAVVYSGN L YFQGAES AAO40254.1
MYOC_Oryctolagus cuniculus GAVVYAGS L YFQGAGS NP_001075619
MYOC_Mus musculus GAVVYAGS L YFQGAES NP_034995.2
MYOC_Rattus norvegicus GAVVYSGS L YFQGAES NP_110492.1
MYOC_Sus scrofa GAVVYQGS L YFQGASS NP_999151.1
MYOC_Bos taurus GAVVYRGS L YFQAAES BAA77298.1
MYOC_Danio rerio (Zebrafish) GATMYKGS L YYQRRLS Q5F0G5
Sequence ID numbers are from the expasy server and NCBI.
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514mutations observed in the homozygous state in the Iranian
patients were among the heterozygous mutations observed in
previous studies [23,25].
Compared  to  these  studies,  the  observation  that
CYP1B1  appears  to  be  the  cause  of  JOAG  in  a  larger
proportion of the patients (17.4%) may not be significant
because of our small sample size. However, it may reflect a
higher frequency of mutated CYP1B1 alleles in the Iranian
gene pool; CYP1B1 has a role in a relatively large percentage
of Iranian PCG patients (70% as compared to 50% for French
and 40% for Indian patients) [28].
With respect to JOAG being associated with one or two
mutated  CYP1B1  alleles,  it  appears  to  be  more  often
associated  with  two  alleles  in  the  Iranian  population.  Of
course, it is possible that in a larger cohort, some JOAG
patients  with  only  one  CYP1B1  mutated  allele  would  be
found.  It  may  be  that  individuals  carrying  one  mutated
CYP1B1 allele will be only mildly symptomatic and therefore
less likely to be identified.
In  conclusion,  our  results  suggest  that  MYOC  and
CYP1B1 are each important in the etiology of JOAG, at least
among Iranians. Precluding possible effects of common SNPs
in the two genes, each appears to be able to promote disease
independently,  and  therefore,  both  MYOC  and  CYP1B1
should be considered potential primary causes of JOAG. It is
thus recommended that both genes be screened for mutations
in individuals at risk, particularly in relatives of glaucoma-
affected individuals known to harbor mutations in these genes.
Non-interventionist treatments are likely to be effective if
applied at early stages of disease progression and could help
prevent irreversible visual impairment.
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